Shirley Wang writes in today’s Wall Street Journal that “scientists studying a four herb combination discovered some 1,800 years ago by Chinese herbalists have found that the substance enhances the effectiveness of chemotherapy in patients with colon cancer.
About interpersonal neurobiology- how the brain constantly rewires itself based on daily life, for example, what we pay the most attention to defines us.
Read the recent NYT article here.
Chade-Meng Tan speaks of everyday compassion at Google. According to Meng compassion works in 3 steps:
The first step is attention training. Attention is the basis of all higher cognitive and emotional abilities. Therefore, any curriculum for training emotion intelligence has to begin with attention training. The idea here is to train attention to create a quality of mind that is calm and clear at the same time. And this creates the foundation for emotion intelligence. The second step follows the first step.
The second step is developing self-knowledge and self-mastery. So using the supercharged attention from step one, we create a high-resolution perception into the cognitive and emotive processes. What does that mean? It means being able to observe our thoughtstream and the process of emotion with high clarity, objectivity and from a third-person perspective. And once you can do that, you create the kind of self-knowledge that enables self-mastery.
The third step, following the second step, is to create new mental habits. What does that mean? Imagine this. Imagine whenever you meet any other person, any time you meet your person, your habitual, instinctive first thought is, “I want you to be happy. I want you to be happy.” Imagine you can do that. Having this habit, this mental habit, changes everything at work. Because this good will is unconsciously picked up by other people, and it creates trust, and trust creates a lot of good working relationships. And this also creates the conditions for compassion in the workplace. Someday, we hope to open-source “Search Inside Yourself” so that everybody in the corporate world will at least be able to use it as a reference.
Here is the video of his recent TED Talk:
Only 3-5 % of adult cancer patients enroll in clinical trials according to the Los Angeles Times. Patients need accurate information to help make informed decisions. UCSF’s Dr. Elly Cohen, program director of a breast cancer clinical trials online matching service, explains to PBS why participation in research is an individual choice and how it can make an impact on care. You can watch it here.
Dr. Susan Desmond-Hellmann explains her translational vision for
fighting cancer during her recent keynote address to UCSF’s breast oncology leaders. She describes 1997 to 2001 as oncology’s golden years. Rituxan, Herceptin and Gleevec debuted and changed the face of cancer treatments. Dr. Desmond-Hellmann believes that academia can today play a critical role in introducing “the platinum age” of cancer drug development.
“Cancer research is too slow, too expensive, too inefficient and too uncertain…we need to understand earlier and with greater confidence what the best ideas are,” she says. Read the full article here.
UCSF Chancellor Susan Desmond-Hellmann discusses the future of oncology
drug development and adaptive clinical trial design and what it means
to patients in an interview with Pharma Strategy Blog’s Sally Church. Here are excerpts from the post:
“What’s really neat about the I-SPY trial is that Laura Esserman, the PI of the trial, is a breast cancer surgeon here at UCSF and has added so much value to the project because she sees patients early and has a unique opportunity to offer neoadjuvant therapy.
Patients are getting their primary therapy before they get surgery, so for imaging and biomarkers – either established or exploratory – it is a fantastic opportunity. The endpoint is pathological complete response, so you can see if the tumor has disappeared or not.”
“It’s a fantastic rapid readout model so you can get answers much more quickly in a year, including pathological specimens, along with the answers from biomarkers and imaging, which are important.
The FDA has allowed a master IND agreement for this study, so it will be possible to move agents in and out of the trial quickly. So if agent A looks promising it can be advanced quickly and more patients put on it, but if agent B looks toxic, it can be discarded quickly. It’s not just a clinical trial but a experimental trial process that gives you a rapid readout of whether the agent works or not.”
“The hope is that you won’t wasting time and money in phase III trials, but most importantly, patients experience on that molecule. If the answer is yes on I-SPY, you then have a biomarker hypothesis for that agent and can then do a more traditional phase III trial having increased your chances of success.”
Read about the i-Spy 2 adaptive clinical trial which was launched on March 17 in Washington.
Watch the video from the Biomarkers Consortium press conference:
UCSF’s Chancellor, Susan Desmond-Hellmann, MD, MPH, was selected by
FORBES as one of its 7 Most Powerful Innovators of 2009. You can read
the story here.
According to the article, Desmond-Hellmann’s most influential
innovations were the blockbuster cancer drugs Avastin and Herceptin. What makes Desmond-Hellmann an innovator?
legions of cancer patients. While president of product development at
Genentech from 2004 to April 2009, she played an integral role in the
selection, testing and development of Avastin, a colon cancer drug with
annual sales of $9 billion, and Herceptin, a breast cancer drug with
sales of $7.8 billion. In August 2009 she became the chancellor of
UCSF, a powerhouse in medical research, where she aims to continue
fostering innovation in health care and science".